Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
PRINCETON, N.J., Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2025.
"As we quickly approach the latter part of 2025 into 2026, the Company remains confident about its late-stage rare disease pipeline and upcoming key development milestones," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "These include top-line results from our Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) before yearend, as well as continued clinical update for the ongoing investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL). Further, we anticipate top-line results in 2026 from our actively enrolling confirmatory Phase 3 study of HyBryte™ (synthetic hypericin) for early-stage CTCL, where we plan to provide an enrollemt update later this year. Recently, we were also pleased to announce the successful completion of our Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease having achieved the study objective of demonstrating biological efficacy in this difficult to treat chronic disease."
Dr. Schaber continued, "With approximately $5.1 million in cash at June 30, 2025, exclusive of approximately $1.4 million of net cash received via our At-The-Market ("ATM") facility on July 1, 2025, we're focused on carefully allocating resources to hit our strategic goals and upcoming milestones. While this cash balance provides sufficient operating runway through the first quarter of 2026, we continue to evaluate all strategic options, including partnership, merger and acquisition, government grants, and potential financing opportunities to advance our late-stage pipeline and the Company."
Soligenix Recent Accomplishments
On July 31, 2025, the Company announced that it had completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease and achieved the study objective of demonstrating biological efficacy. To view this press release, please click here.
On July 8, 2025, the Company issued a shareholder update letter, detailing the important and potentially transformational development milestones. To view this letter, please click here.
On July 1, 2025, the Company announced it had successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient from Europe ...
